Wedbush Issues Positive Forecast for Biogen Earnings

Biogen Inc. (NASDAQ:BIIB - Free Report) - Wedbush increased their Q2 2025 earnings per share estimates for Biogen in a research note issued on Wednesday, April 16th. Wedbush analyst L. Chico now expects that the biotechnology company will post earnings per share of $4.21 for the quarter, up from their prior forecast of $3.98. The consensus estimate for Biogen's current full-year earnings is $15.83 per share. Wedbush also issued estimates for Biogen's Q3 2025 earnings at $4.12 EPS, Q4 2025 earnings at $3.87 EPS, FY2025 earnings at $15.71 EPS, Q3 2026 earnings at $4.33 EPS, FY2028 earnings at $20.48 EPS and FY2029 earnings at $21.14 EPS.

Biogen (NASDAQ:BIIB - Get Free Report) last announced its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported $3.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.43 by $0.01. Biogen had a net margin of 16.87% and a return on equity of 14.98%.

BIIB has been the topic of a number of other research reports. Royal Bank of Canada boosted their target price on shares of Biogen from $221.00 to $225.00 and gave the company an "outperform" rating in a report on Tuesday. StockNews.com cut shares of Biogen from a "strong-buy" rating to a "buy" rating in a report on Saturday, December 28th. Piper Sandler reaffirmed a "neutral" rating and set a $135.00 target price (down previously from $138.00) on shares of Biogen in a research note on Tuesday, February 18th. Bank Of America (Bofa) dropped their price target on Biogen from $178.00 to $163.00 and set a "neutral" rating on the stock in a research report on Tuesday, February 11th. Finally, Truist Financial reduced their price objective on Biogen from $220.00 to $210.00 and set a "buy" rating for the company in a research report on Thursday, February 13th. Eighteen research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $211.37.

Biogen Stock Down 0.7 %

Shares of BIIB traded down $0.83 on Friday, reaching $118.06. The stock had a trading volume of 1,249,027 shares, compared to its average volume of 1,355,162. The company has a debt-to-equity ratio of 0.27, a quick ratio of 0.90 and a current ratio of 1.35. Biogen has a 12-month low of $110.04 and a 12-month high of $238.00. The firm has a market capitalization of $17.28 billion, a price-to-earnings ratio of 10.55, a price-to-earnings-growth ratio of 1.51 and a beta of 0.06. The company has a 50-day simple moving average of $133.56 and a 200-day simple moving average of $150.49.

Hedge Funds Weigh In On Biogen

A number of hedge funds and other institutional investors have recently modified their holdings of BIIB. Inspire Trust Co. N.A. increased its position in Biogen by 58.5% in the third quarter. Inspire Trust Co. N.A. now owns 10,900 shares of the biotechnology company's stock worth $2,113,000 after purchasing an additional 4,025 shares during the last quarter. Assenagon Asset Management S.A. raised its holdings in Biogen by 0.3% during the 4th quarter. Assenagon Asset Management S.A. now owns 43,460 shares of the biotechnology company's stock valued at $6,646,000 after buying an additional 111 shares during the period. Amundi lifted its position in Biogen by 35.6% in the fourth quarter. Amundi now owns 1,216,990 shares of the biotechnology company's stock worth $183,461,000 after buying an additional 319,478 shares during the last quarter. Centre Asset Management LLC boosted its stake in Biogen by 7.7% during the fourth quarter. Centre Asset Management LLC now owns 51,530 shares of the biotechnology company's stock worth $7,880,000 after buying an additional 3,698 shares during the period. Finally, Integrated Quantitative Investments LLC bought a new position in Biogen during the fourth quarter valued at $407,000. Institutional investors own 87.93% of the company's stock.

Insider Buying and Selling

In other Biogen news, Director Stephen A. Sherwin sold 8,760 shares of the stock in a transaction on Friday, March 7th. The stock was sold at an average price of $150.02, for a total value of $1,314,175.20. Following the completion of the sale, the director now owns 11,318 shares in the company, valued at approximately $1,697,926.36. This represents a 43.63 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.16% of the stock is currently owned by insiders.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.